EXINI Diagnostics AB
EXINI’s biomarker BSI for oral presentation at SNMMI
DGAP-News: EXINI Diagnostics AB 2015-05-25 / 08:52 --------------------------------------------------------------------- Lund, Sweden, 2015-05-25 08:52 CEST (GLOBE NEWSWIRE) -- A new study of the imaging biomarker Bone Scan Index (BSI) has qualified for oral presentation at the 2015 SNMMI (Society of Nuclear Medicine and Molecular Imaging) annual meeting, 6-10th of June, in Baltimore, USA. The congress is regarded as the leading congress within nuclear medicine, attracting 4 000 world-leading experts. The SNMMI-congress brings together experts within molecular imaging and nuclear medicine with leading radiologists, radio-pharmacists, scientists, technicians and medical laboratory scientists from prominent medical and academic institutions and centres world-wide. 'For the first time a BSI-study will be presented at this, the largest and most renowned congress for nuclear medicine professionals. The majority of participants will be US nuclear medicine physicists, that's why this presentation is instrumental in generating interest and spreading knowledge about BSI and the software EXINI boneBSI to the US market', comments Magnus Aurell, CEO, EXINI Diagnostics AB. Details on the BSI-presentation: 'Analytical validation of automated Bone Scan index (BSI) as an imaging biomarker in patients with metastatic prostate cancer (mPC)' by Aseem Anand, Michael J Morris, David Minarik, Anders Bjartell, and Lars Edenbrandt at Memorial Sloan Kettering Cancer Center, New York, US, and Lund University, Malmö, Sweden. For details on the presentation, please visit: http://snmmi.staging.m.eventsential.org/Sessions/Details/78063 More on Bone Scan Index (BSI): BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnosis and stratification and the monitoring of treatment response. It also provides increased accuracy in prognoses involving patients suffering from skeletal metastases originating from prostate or breast cancer. Moreover, BSI has demonstrated its importance in the process of developing new drugs, thus proving itself just as important for clinical use as for the pharmaceutical industry. EXINI boneBSI is the only software capable of calculating the BSI-value. www.bonescanindex.org www.exini.com/software/exini-bone-bsi/ For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ OMX First North and has about 1000 shareholders. Consensus acts as Certified Adviser. ________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-05-25 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: EXINI Diagnostics AB Sweden ISIN: SE0001810284 End of News DGAP News-Service --------------------------------------------------------------------- 361421 2015-05-25
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden